Biomarkers for Alzheimer's disease: Showing the way or leading us astray?

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Quinn, Joseph F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; biomarkers; clinical trials

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; CCL15 CHEMOKINE; CHEMOKINE; DEATH RECEPTOR 4; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84872571276     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129022     Document Type: Review

References (15)

1. Li G, Sokal I, Quinn JF, Leverenz JB, BrodeyM, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69, 631-639
2. Bowman GL, Kaye JA,Moore M,Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology 68, 1809-1814
3. Quinn JF,Montine KS, Moore M, MorrowJD, Kaye JA,Montine TJ (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6, 93-97
4. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348
5. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129, 526-529
6. Bowman GL, Dodge H, Frei B, Calabrese C, Oken BS, Kaye JA, Quinn JF (2009) Ascorbic acid and rates of cognitive decline in Alzheimer's disease. J Alzheimers Dis 16, 93-98
7. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19, 1331-1336
8. Lehmann M, Regland B, Blennow K, Gottfries CG (2003) Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord 16, 145-150
9. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362
10. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-Secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604
11. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gammasecretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038
12. Schor NF (2011) What the halted phase III gamma-Secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69, 237-239
13. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease:Arandomized controlled trial. JAMA 302, 2557-2564
14. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-To-Moderate Alzheimer's disease: Results from a randomized, doubleblind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30, 131-146
15. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 304, 1903-1911